Market Overview

Echo Therapeutics Announces Positive Clinical Trial Results of Symphony® tCGM System


Echo Therapeutics, Inc. (Nasdaq: ECTE) today announced positive results from its clinical trial of the Symphony tCGM System in major general surgery and cardiothoracic surgery patients. This study is the second of two studies in critically ill patients.

Data from this study demonstrate that Symphony successfully and continuously monitored glucose levels in the intensive care unit at Thomas Jefferson University Hospital in Philadelphia, Pennsylvania. Data analysis demonstrated that Symphony accurately read glucose levels with a mean absolute relative difference (MARD), or error rate of 9.0%. The Continuous Glucose-Error Grid analysis (CG-EGA) showed that 98.9% of the readings were clinically accurate (A) and 0.3% were benign (B) errors with a combined A+B of 99.2%

Posted-In: News FDA


Related Articles (ECTE)

View Comments and Join the Discussion!

Partner Center